{
    "medicine_id": "02c58c088d1d13b46b8f523fa6aa7381e339a406",
    "platform_id": "DB15719",
    "metadata": {
        "name": "Blenrep 50 mg 1mL Injection powder lyophilized for solution",
        "composition": "50 mg 1mL Belantamab mafodotin",
        "clinical_particulars": {
            "therapeutic_indications": "Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti CD38 monoclonal antibody a proteasome inhibitor and an immunomodulatory agent L15326",
            "contraindications": {
                "disease": "Data regarding overdose is not readily available L15326 However keratopathy was seen in 71 of patients A216756 A216761 A216766 L15326",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Belantamab mafodotin treats multiple myeloma through antibody dependant cell mediated cytotoxicity as well as G2 M cell cycle arrest A216771 It has a narrow therapeutic index due to the incidence of adverse effects and a long duration of action as it is given every 3 weeks L15326 Patients should be counselled regarding the risk of keratopathy L15326",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00091",
                        "description": "Cyclosporine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00197",
                        "description": "Troglitazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00199",
                        "description": "Erythromycin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00206",
                        "description": "Reserpine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00275",
                        "description": "Olmesartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00396",
                        "description": "Progesterone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00477",
                        "description": "Chlorpromazine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00482",
                        "description": "Celecoxib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00501",
                        "description": "Cimetidine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00559",
                        "description": "Bosentan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00675",
                        "description": "Tamoxifen may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00908",
                        "description": "Quinidine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00932",
                        "description": "Tipranavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00977",
                        "description": "Ethinylestradiol may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01016",
                        "description": "Glyburide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01026",
                        "description": "Ketoconazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01045",
                        "description": "Rifampicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01115",
                        "description": "Nifedipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01586",
                        "description": "Ursodeoxycholic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB02659",
                        "description": "Cholic Acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB02703",
                        "description": "Fusidic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB06290",
                        "description": "Simeprevir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB09078",
                        "description": "Lenvatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB12070",
                        "description": "Letermovir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB14057",
                        "description": "Valinomycin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB15822",
                        "description": "Pralsetinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00243",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ranolazine"
                    },
                    {
                        "drugbank-id": "DB00269",
                        "description": "Chlorotrianisene may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00286",
                        "description": "Conjugated estrogens may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00655",
                        "description": "Estrone may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00783",
                        "description": "Estradiol may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00890",
                        "description": "Dienestrol may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB01357",
                        "description": "Mestranol may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB04573",
                        "description": "Estriol may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB04574",
                        "description": "Estrone sulfate may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB04575",
                        "description": "Quinestrol may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB07931",
                        "description": "Hexestrol may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09070",
                        "description": "Tibolone may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09317",
                        "description": "Synthetic Conjugated Estrogens A may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09318",
                        "description": "Synthetic Conjugated Estrogens B may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09369",
                        "description": "Polyestradiol phosphate may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09381",
                        "description": "Esterified estrogens may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11478",
                        "description": "Zeranol may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11674",
                        "description": "Equol may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12487",
                        "description": "Promestriene may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13143",
                        "description": "Methallenestril may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13386",
                        "description": "Epimestrol may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13418",
                        "description": "Moxestrol may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13952",
                        "description": "Estradiol acetate may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13953",
                        "description": "Estradiol benzoate may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13954",
                        "description": "Estradiol cypionate may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13956",
                        "description": "Estradiol valerate may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15334",
                        "description": "Biochanin A may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15335",
                        "description": "Formononetin may increase the thrombogenic activities of Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09280",
                        "description": "The serum concentration of Belantamab mafodotin can be decreased when it is combined with Lumacaftor"
                    },
                    {
                        "drugbank-id": "DB08881",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Vemurafenib"
                    },
                    {
                        "drugbank-id": "DB11901",
                        "description": "The serum concentration of Belantamab mafodotin can be decreased when it is combined with Apalutamide"
                    },
                    {
                        "drugbank-id": "DB11642",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Pitolisant"
                    },
                    {
                        "drugbank-id": "DB06636",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Isavuconazonium"
                    },
                    {
                        "drugbank-id": "DB11633",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Isavuconazole"
                    },
                    {
                        "drugbank-id": "DB00196",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Fluconazole"
                    },
                    {
                        "drugbank-id": "DB00203",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Sildenafil"
                    },
                    {
                        "drugbank-id": "DB00398",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Sorafenib"
                    },
                    {
                        "drugbank-id": "DB00408",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Loxapine"
                    },
                    {
                        "drugbank-id": "DB00468",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Quinine"
                    },
                    {
                        "drugbank-id": "DB00503",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ritonavir"
                    },
                    {
                        "drugbank-id": "DB00539",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Toremifene"
                    },
                    {
                        "drugbank-id": "DB00641",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Simvastatin"
                    },
                    {
                        "drugbank-id": "DB00661",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Verapamil"
                    },
                    {
                        "drugbank-id": "DB00834",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Mifepristone"
                    },
                    {
                        "drugbank-id": "DB00845",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Clofazimine"
                    },
                    {
                        "drugbank-id": "DB00862",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Vardenafil"
                    },
                    {
                        "drugbank-id": "DB00864",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Tacrolimus"
                    },
                    {
                        "drugbank-id": "DB00872",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Conivaptan"
                    },
                    {
                        "drugbank-id": "DB00909",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Zonisamide"
                    },
                    {
                        "drugbank-id": "DB00957",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Norgestimate"
                    },
                    {
                        "drugbank-id": "DB01118",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Amiodarone"
                    },
                    {
                        "drugbank-id": "DB01136",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Carvedilol"
                    },
                    {
                        "drugbank-id": "DB01167",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Itraconazole"
                    },
                    {
                        "drugbank-id": "DB01182",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Propafenone"
                    },
                    {
                        "drugbank-id": "DB01211",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Clarithromycin"
                    },
                    {
                        "drugbank-id": "DB01232",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Saquinavir"
                    },
                    {
                        "drugbank-id": "DB01259",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Lapatinib"
                    },
                    {
                        "drugbank-id": "DB01267",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Paliperidone"
                    },
                    {
                        "drugbank-id": "DB01388",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Mibefradil"
                    },
                    {
                        "drugbank-id": "DB01601",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Lopinavir"
                    },
                    {
                        "drugbank-id": "DB04851",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Biricodar"
                    },
                    {
                        "drugbank-id": "DB04855",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Dronedarone"
                    },
                    {
                        "drugbank-id": "DB04868",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Nilotinib"
                    },
                    {
                        "drugbank-id": "DB04881",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Elacridar"
                    },
                    {
                        "drugbank-id": "DB04908",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Flibanserin"
                    },
                    {
                        "drugbank-id": "DB05294",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Vandetanib"
                    },
                    {
                        "drugbank-id": "DB05521",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Telaprevir"
                    },
                    {
                        "drugbank-id": "DB06191",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Zosuquidar"
                    },
                    {
                        "drugbank-id": "DB06240",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Tariquidar"
                    },
                    {
                        "drugbank-id": "DB06287",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Temsirolimus"
                    },
                    {
                        "drugbank-id": "DB06448",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Lonafarnib"
                    },
                    {
                        "drugbank-id": "DB07348",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Brefeldin A"
                    },
                    {
                        "drugbank-id": "DB08816",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ticagrelor"
                    },
                    {
                        "drugbank-id": "DB08820",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ivacaftor"
                    },
                    {
                        "drugbank-id": "DB08827",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Lomitapide"
                    },
                    {
                        "drugbank-id": "DB08865",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Crizotinib"
                    },
                    {
                        "drugbank-id": "DB08882",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Linagliptin"
                    },
                    {
                        "drugbank-id": "DB08889",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Carfilzomib"
                    },
                    {
                        "drugbank-id": "DB08893",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Mirabegron"
                    },
                    {
                        "drugbank-id": "DB08896",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Regorafenib"
                    },
                    {
                        "drugbank-id": "DB08899",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Enzalutamide"
                    },
                    {
                        "drugbank-id": "DB08901",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ponatinib"
                    },
                    {
                        "drugbank-id": "DB08907",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Canagliflozin"
                    },
                    {
                        "drugbank-id": "DB08916",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Afatinib"
                    },
                    {
                        "drugbank-id": "DB09027",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ledipasvir"
                    },
                    {
                        "drugbank-id": "DB09030",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Vorapaxar"
                    },
                    {
                        "drugbank-id": "DB09034",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Suvorexant"
                    },
                    {
                        "drugbank-id": "DB09048",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Netupitant"
                    },
                    {
                        "drugbank-id": "DB09065",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Cobicistat"
                    },
                    {
                        "drugbank-id": "DB09073",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Palbociclib"
                    },
                    {
                        "drugbank-id": "DB09102",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Daclatasvir"
                    },
                    {
                        "drugbank-id": "DB09239",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Niguldipine"
                    },
                    {
                        "drugbank-id": "DB09241",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Methylene blue"
                    },
                    {
                        "drugbank-id": "DB09291",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Rolapitant"
                    },
                    {
                        "drugbank-id": "DB11581",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Venetoclax"
                    },
                    {
                        "drugbank-id": "DB11586",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Asunaprevir"
                    },
                    {
                        "drugbank-id": "DB11613",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Velpatasvir"
                    },
                    {
                        "drugbank-id": "DB11753",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Rifamycin"
                    },
                    {
                        "drugbank-id": "DB11757",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Istradefylline"
                    },
                    {
                        "drugbank-id": "DB11828",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Neratinib"
                    },
                    {
                        "drugbank-id": "DB11869",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Valspodar"
                    },
                    {
                        "drugbank-id": "DB11963",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Dacomitinib"
                    },
                    {
                        "drugbank-id": "DB11978",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Glasdegib"
                    },
                    {
                        "drugbank-id": "DB11979",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Elagolix"
                    },
                    {
                        "drugbank-id": "DB11986",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Entrectinib"
                    },
                    {
                        "drugbank-id": "DB12026",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Voxilaprevir"
                    },
                    {
                        "drugbank-id": "DB12035",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Sarecycline"
                    },
                    {
                        "drugbank-id": "DB12332",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Rucaparib"
                    },
                    {
                        "drugbank-id": "DB12466",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Favipiravir"
                    },
                    {
                        "drugbank-id": "DB12500",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Fedratinib"
                    },
                    {
                        "drugbank-id": "DB12799",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Laniquidar"
                    },
                    {
                        "drugbank-id": "DB13874",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Enasidenib"
                    },
                    {
                        "drugbank-id": "DB13878",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Pibrentasvir"
                    },
                    {
                        "drugbank-id": "DB13879",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Glecaprevir"
                    },
                    {
                        "drugbank-id": "DB14068",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Dexniguldipine"
                    },
                    {
                        "drugbank-id": "DB14069",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with ONT 093"
                    },
                    {
                        "drugbank-id": "DB14568",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ivosidenib"
                    },
                    {
                        "drugbank-id": "DB14840",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ripretinib"
                    },
                    {
                        "drugbank-id": "DB00002",
                        "description": "The risk or severity of adverse effects can be increased when Cetuximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00028",
                        "description": "The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00043",
                        "description": "The risk or severity of adverse effects can be increased when Omalizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00051",
                        "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00054",
                        "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00056",
                        "description": "The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00057",
                        "description": "The risk or severity of adverse effects can be increased when Indium In 111 satumomab pendetide is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00065",
                        "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00072",
                        "description": "The risk or severity of adverse effects can be increased when Trastuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00073",
                        "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00074",
                        "description": "The risk or severity of adverse effects can be increased when Basiliximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00075",
                        "description": "The risk or severity of adverse effects can be increased when Muromonab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00076",
                        "description": "The risk or severity of adverse effects can be increased when Digoxin Immune Fab Ovine is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00078",
                        "description": "The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00081",
                        "description": "The risk or severity of adverse effects can be increased when Tositumomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00087",
                        "description": "The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00089",
                        "description": "The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00095",
                        "description": "The risk or severity of adverse effects can be increased when Efalizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00098",
                        "description": "The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin rabbit is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00108",
                        "description": "The risk or severity of adverse effects can be increased when Natalizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00110",
                        "description": "The risk or severity of adverse effects can be increased when Palivizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00111",
                        "description": "The risk or severity of adverse effects can be increased when Daclizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00112",
                        "description": "The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00113",
                        "description": "The risk or severity of adverse effects can be increased when Technetium Tc 99m arcitumomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB01257",
                        "description": "The risk or severity of adverse effects can be increased when Eculizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB01269",
                        "description": "The risk or severity of adverse effects can be increased when Panitumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB01270",
                        "description": "The risk or severity of adverse effects can be increased when Ranibizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB04901",
                        "description": "The risk or severity of adverse effects can be increased when Galiximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB04949",
                        "description": "The risk or severity of adverse effects can be increased when Pexelizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB04956",
                        "description": "The risk or severity of adverse effects can be increased when Afelimomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB04958",
                        "description": "The risk or severity of adverse effects can be increased when Epratuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB04962",
                        "description": "The risk or severity of adverse effects can be increased when Bectumomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB04964",
                        "description": "The risk or severity of adverse effects can be increased when Oregovomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB04988",
                        "description": "The risk or severity of adverse effects can be increased when IGN311 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05006",
                        "description": "The risk or severity of adverse effects can be increased when Adecatumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05097",
                        "description": "The risk or severity of adverse effects can be increased when Labetuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05101",
                        "description": "The risk or severity of adverse effects can be increased when Matuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05111",
                        "description": "The risk or severity of adverse effects can be increased when Fontolizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05136",
                        "description": "The risk or severity of adverse effects can be increased when Bavituximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05139",
                        "description": "The risk or severity of adverse effects can be increased when CR002 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05209",
                        "description": "The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05304",
                        "description": "The risk or severity of adverse effects can be increased when Girentuximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05336",
                        "description": "The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05405",
                        "description": "The risk or severity of adverse effects can be increased when XTL 001 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05437",
                        "description": "The risk or severity of adverse effects can be increased when NAV 1800 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05459",
                        "description": "The risk or severity of adverse effects can be increased when Briakinumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05496",
                        "description": "The risk or severity of adverse effects can be increased when Otelixizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05545",
                        "description": "The risk or severity of adverse effects can be increased when AMG 108 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05550",
                        "description": "The risk or severity of adverse effects can be increased when Iratumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05555",
                        "description": "The risk or severity of adverse effects can be increased when Enokizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05578",
                        "description": "The risk or severity of adverse effects can be increased when Ramucirumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05595",
                        "description": "The risk or severity of adverse effects can be increased when Farletuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05656",
                        "description": "The risk or severity of adverse effects can be increased when Veltuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05679",
                        "description": "The risk or severity of adverse effects can be increased when Ustekinumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05793",
                        "description": "The risk or severity of adverse effects can be increased when PRO 542 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05797",
                        "description": "The risk or severity of adverse effects can be increased when TNX 901 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05892",
                        "description": "The risk or severity of adverse effects can be increased when RI 624 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05915",
                        "description": "The risk or severity of adverse effects can be increased when MYO 029 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05916",
                        "description": "The risk or severity of adverse effects can be increased when CT 011 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05941",
                        "description": "The risk or severity of adverse effects can be increased when Leronlimab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB05996",
                        "description": "The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06043",
                        "description": "The risk or severity of adverse effects can be increased when Olaratumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06049",
                        "description": "The risk or severity of adverse effects can be increased when IPH 2101 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06050",
                        "description": "The risk or severity of adverse effects can be increased when TB 402 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06081",
                        "description": "The risk or severity of adverse effects can be increased when Caplacizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06101",
                        "description": "The risk or severity of adverse effects can be increased when IMC 1C11 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06116",
                        "description": "The risk or severity of adverse effects can be increased when Eldelumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06162",
                        "description": "The risk or severity of adverse effects can be increased when Lumiliximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06168",
                        "description": "The risk or severity of adverse effects can be increased when Canakinumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06186",
                        "description": "The risk or severity of adverse effects can be increased when Ipilimumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06192",
                        "description": "The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06241",
                        "description": "The risk or severity of adverse effects can be increased when Clenoliximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06273",
                        "description": "The risk or severity of adverse effects can be increased when Tocilizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06304",
                        "description": "The risk or severity of adverse effects can be increased when BIIB015 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06305",
                        "description": "The risk or severity of adverse effects can be increased when Sonepcizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06310",
                        "description": "The risk or severity of adverse effects can be increased when Motavizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06317",
                        "description": "The risk or severity of adverse effects can be increased when Elotuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06318",
                        "description": "The risk or severity of adverse effects can be increased when AVE9633 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06322",
                        "description": "The risk or severity of adverse effects can be increased when Carotuximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06324",
                        "description": "The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06342",
                        "description": "The risk or severity of adverse effects can be increased when Coltuximab ravtansine is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06343",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06360",
                        "description": "The risk or severity of adverse effects can be increased when Lucatumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06366",
                        "description": "The risk or severity of adverse effects can be increased when Pertuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06371",
                        "description": "The risk or severity of adverse effects can be increased when Siplizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06467",
                        "description": "The risk or severity of adverse effects can be increased when Apolizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06474",
                        "description": "The risk or severity of adverse effects can be increased when Sibrotuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06550",
                        "description": "The risk or severity of adverse effects can be increased when Bivatuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06557",
                        "description": "The risk or severity of adverse effects can be increased when Lerdelimumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06599",
                        "description": "The risk or severity of adverse effects can be increased when Lexatumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06602",
                        "description": "The risk or severity of adverse effects can be increased when Reslizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06606",
                        "description": "The risk or severity of adverse effects can be increased when Teplizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06607",
                        "description": "The risk or severity of adverse effects can be increased when Catumaxomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06612",
                        "description": "The risk or severity of adverse effects can be increased when Mepolizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06643",
                        "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06647",
                        "description": "The risk or severity of adverse effects can be increased when Volociximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06650",
                        "description": "The risk or severity of adverse effects can be increased when Ofatumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06674",
                        "description": "The risk or severity of adverse effects can be increased when Golimumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB08879",
                        "description": "The risk or severity of adverse effects can be increased when Belimumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB08902",
                        "description": "The risk or severity of adverse effects can be increased when Raxibacumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB08904",
                        "description": "The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB08935",
                        "description": "The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09029",
                        "description": "The risk or severity of adverse effects can be increased when Secukinumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09033",
                        "description": "The risk or severity of adverse effects can be increased when Vedolizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09035",
                        "description": "The risk or severity of adverse effects can be increased when Nivolumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09036",
                        "description": "The risk or severity of adverse effects can be increased when Siltuximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09037",
                        "description": "The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09045",
                        "description": "The risk or severity of adverse effects can be increased when Dulaglutide is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09052",
                        "description": "The risk or severity of adverse effects can be increased when Blinatumomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09057",
                        "description": "The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09077",
                        "description": "The risk or severity of adverse effects can be increased when Dinutuximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09105",
                        "description": "The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09264",
                        "description": "The risk or severity of adverse effects can be increased when Idarucizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09302",
                        "description": "The risk or severity of adverse effects can be increased when Alirocumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09303",
                        "description": "The risk or severity of adverse effects can be increased when Evolocumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09312",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09331",
                        "description": "The risk or severity of adverse effects can be increased when Daratumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09559",
                        "description": "The risk or severity of adverse effects can be increased when Necitumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11569",
                        "description": "The risk or severity of adverse effects can be increased when Ixekizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11580",
                        "description": "The risk or severity of adverse effects can be increased when Ravulizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11595",
                        "description": "The risk or severity of adverse effects can be increased when Atezolizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11604",
                        "description": "The risk or severity of adverse effects can be increased when Tetanus Immune Globulin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11608",
                        "description": "The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11621",
                        "description": "The risk or severity of adverse effects can be increased when Human Varicella Zoster Immune Globulin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11646",
                        "description": "The risk or severity of adverse effects can be increased when Conatumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11657",
                        "description": "The risk or severity of adverse effects can be increased when Tabalumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11680",
                        "description": "The risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11685",
                        "description": "The risk or severity of adverse effects can be increased when Figitumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11714",
                        "description": "The risk or severity of adverse effects can be increased when Durvalumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11715",
                        "description": "The risk or severity of adverse effects can be increased when Bapineuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11731",
                        "description": "The risk or severity of adverse effects can be increased when Depatuxizumab mafodotin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11746",
                        "description": "The risk or severity of adverse effects can be increased when Onartuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11756",
                        "description": "The risk or severity of adverse effects can be increased when Solanezumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11767",
                        "description": "The risk or severity of adverse effects can be increased when Sarilumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11771",
                        "description": "The risk or severity of adverse effects can be increased when Tremelimumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11776",
                        "description": "The risk or severity of adverse effects can be increased when Brodalumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11803",
                        "description": "The risk or severity of adverse effects can be increased when Sirukumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11826",
                        "description": "The risk or severity of adverse effects can be increased when Lampalizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11834",
                        "description": "The risk or severity of adverse effects can be increased when Guselkumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11840",
                        "description": "The risk or severity of adverse effects can be increased when Dalotuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11849",
                        "description": "The risk or severity of adverse effects can be increased when Emibetuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11850",
                        "description": "The risk or severity of adverse effects can be increased when Ublituximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11856",
                        "description": "The risk or severity of adverse effects can be increased when Ligelizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11857",
                        "description": "The risk or severity of adverse effects can be increased when Seribantumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11862",
                        "description": "The risk or severity of adverse effects can be increased when Landogrozumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11866",
                        "description": "The risk or severity of adverse effects can be increased when Romosozumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11884",
                        "description": "The risk or severity of adverse effects can be increased when Vadastuximab Talirine is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11914",
                        "description": "The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11930",
                        "description": "The risk or severity of adverse effects can be increased when Varlilumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11945",
                        "description": "The risk or severity of adverse effects can be increased when Avelumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11959",
                        "description": "The risk or severity of adverse effects can be increased when Crenezumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11972",
                        "description": "The risk or severity of adverse effects can be increased when Rilotumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11976",
                        "description": "The risk or severity of adverse effects can be increased when Anifrolumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11988",
                        "description": "The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12023",
                        "description": "The risk or severity of adverse effects can be increased when Benralizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12034",
                        "description": "The risk or severity of adverse effects can be increased when Gantenerumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12053",
                        "description": "The risk or severity of adverse effects can be increased when Visilizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12077",
                        "description": "The risk or severity of adverse effects can be increased when Urelumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12089",
                        "description": "The risk or severity of adverse effects can be increased when Lorvotuzumab mertansine is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12090",
                        "description": "The risk or severity of adverse effects can be increased when Patritumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12102",
                        "description": "The risk or severity of adverse effects can be increased when Fulranumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12104",
                        "description": "The risk or severity of adverse effects can be increased when Tarextumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12118",
                        "description": "The risk or severity of adverse effects can be increased when Sotatercept is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12119",
                        "description": "The risk or severity of adverse effects can be increased when Gevokizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12142",
                        "description": "The risk or severity of adverse effects can be increased when Duligotuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12152",
                        "description": "The risk or severity of adverse effects can be increased when Simtuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12157",
                        "description": "The risk or severity of adverse effects can be increased when Fasinumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12159",
                        "description": "The risk or severity of adverse effects can be increased when Dupilumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12169",
                        "description": "The risk or severity of adverse effects can be increased when Tralokinumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12189",
                        "description": "The risk or severity of adverse effects can be increased when Etrolizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12202",
                        "description": "The risk or severity of adverse effects can be increased when Zalutumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12205",
                        "description": "The risk or severity of adverse effects can be increased when Ganitumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12213",
                        "description": "The risk or severity of adverse effects can be increased when Etaracizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12240",
                        "description": "The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12246",
                        "description": "The risk or severity of adverse effects can be increased when Inclacumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12250",
                        "description": "The risk or severity of adverse effects can be increased when Cixutumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12261",
                        "description": "The risk or severity of adverse effects can be increased when Ascrinvacumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12274",
                        "description": "The risk or severity of adverse effects can be increased when Aducanumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12281",
                        "description": "The risk or severity of adverse effects can be increased when Luspatercept is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12296",
                        "description": "The risk or severity of adverse effects can be increased when GS 5745 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12317",
                        "description": "The risk or severity of adverse effects can be increased when Vanucizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12331",
                        "description": "The risk or severity of adverse effects can be increased when Labetuzumab govitecan is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12335",
                        "description": "The risk or severity of adverse effects can be increased when Tanezumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12342",
                        "description": "The risk or severity of adverse effects can be increased when Ensituximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12344",
                        "description": "The risk or severity of adverse effects can be increased when Fezakinumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12363",
                        "description": "The risk or severity of adverse effects can be increased when Dusigitumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12396",
                        "description": "The risk or severity of adverse effects can be increased when Fresolimumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12413",
                        "description": "The risk or severity of adverse effects can be increased when Indusatumab vedotin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12456",
                        "description": "The risk or severity of adverse effects can be increased when Bococizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12489",
                        "description": "The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12498",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12520",
                        "description": "The risk or severity of adverse effects can be increased when Plozalizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12530",
                        "description": "The risk or severity of adverse effects can be increased when Inebilizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12534",
                        "description": "The risk or severity of adverse effects can be increased when Mavrilimumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12560",
                        "description": "The risk or severity of adverse effects can be increased when Blosozumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12584",
                        "description": "The risk or severity of adverse effects can be increased when Bimagrumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12589",
                        "description": "The risk or severity of adverse effects can be increased when Dacetuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12609",
                        "description": "The risk or severity of adverse effects can be increased when Tovetumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12683",
                        "description": "The risk or severity of adverse effects can be increased when Lumretuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12698",
                        "description": "The risk or severity of adverse effects can be increased when Ibalizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12701",
                        "description": "The risk or severity of adverse effects can be increased when Intetumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12718",
                        "description": "The risk or severity of adverse effects can be increased when Carlumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12734",
                        "description": "The risk or severity of adverse effects can be increased when Demcizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12773",
                        "description": "The risk or severity of adverse effects can be increased when Sifalimumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12775",
                        "description": "The risk or severity of adverse effects can be increased when Abituzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12797",
                        "description": "The risk or severity of adverse effects can be increased when Ecromeximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12807",
                        "description": "The risk or severity of adverse effects can be increased when Naptumomab Estafenatox is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12815",
                        "description": "The risk or severity of adverse effects can be increased when Crotedumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12820",
                        "description": "The risk or severity of adverse effects can be increased when Concizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12826",
                        "description": "The risk or severity of adverse effects can be increased when Depatuxizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12844",
                        "description": "The risk or severity of adverse effects can be increased when Rontalizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12845",
                        "description": "The risk or severity of adverse effects can be increased when Amatuximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12849",
                        "description": "The risk or severity of adverse effects can be increased when Clazakizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12891",
                        "description": "The risk or severity of adverse effects can be increased when Ozanezumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12893",
                        "description": "The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12917",
                        "description": "The risk or severity of adverse effects can be increased when Bimekizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12943",
                        "description": "The risk or severity of adverse effects can be increased when Milatuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12976",
                        "description": "The risk or severity of adverse effects can be increased when Robatumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13017",
                        "description": "The risk or severity of adverse effects can be increased when Rovalpituzumab Tesirine is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13037",
                        "description": "The risk or severity of adverse effects can be increased when Namilumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13045",
                        "description": "The risk or severity of adverse effects can be increased when Racotumomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13073",
                        "description": "The risk or severity of adverse effects can be increased when Tregalizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13127",
                        "description": "The risk or severity of adverse effects can be increased when Olokizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13140",
                        "description": "The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13375",
                        "description": "The risk or severity of adverse effects can be increased when Edrecolomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13535",
                        "description": "The risk or severity of adverse effects can be increased when Nebacumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13886",
                        "description": "The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13923",
                        "description": "The risk or severity of adverse effects can be increased when Emicizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13976",
                        "description": "The risk or severity of adverse effects can be increased when Sulesomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB13979",
                        "description": "The risk or severity of adverse effects can be increased when Besilesomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14004",
                        "description": "The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14012",
                        "description": "The risk or severity of adverse effects can be increased when Burosumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14039",
                        "description": "The risk or severity of adverse effects can be increased when Erenumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14040",
                        "description": "The risk or severity of adverse effects can be increased when Eptinezumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14041",
                        "description": "The risk or severity of adverse effects can be increased when Fremanezumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14042",
                        "description": "The risk or severity of adverse effects can be increased when Galcanezumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14211",
                        "description": "The risk or severity of adverse effects can be increased when Fanolesomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14580",
                        "description": "The risk or severity of adverse effects can be increased when Lecanemab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14597",
                        "description": "The risk or severity of adverse effects can be increased when Lanadelumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14707",
                        "description": "The risk or severity of adverse effects can be increased when Cemiplimab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14724",
                        "description": "The risk or severity of adverse effects can be increased when Emapalumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14762",
                        "description": "The risk or severity of adverse effects can be increased when Risankizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14776",
                        "description": "The risk or severity of adverse effects can be increased when Camrelizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14778",
                        "description": "The risk or severity of adverse effects can be increased when Setrusumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14784",
                        "description": "The risk or severity of adverse effects can be increased when Gancotamab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14809",
                        "description": "The risk or severity of adverse effects can be increased when Anetumab ravtansine is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14811",
                        "description": "The risk or severity of adverse effects can be increased when Isatuximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14824",
                        "description": "The risk or severity of adverse effects can be increased when Icrucumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14843",
                        "description": "The risk or severity of adverse effects can be increased when Codrituzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14864",
                        "description": "The risk or severity of adverse effects can be increased when Brolucizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14871",
                        "description": "The risk or severity of adverse effects can be increased when Xentuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14877",
                        "description": "The risk or severity of adverse effects can be increased when Lintuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14891",
                        "description": "The risk or severity of adverse effects can be increased when Vobarilizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14897",
                        "description": "The risk or severity of adverse effects can be increased when Parsatuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14905",
                        "description": "The risk or severity of adverse effects can be increased when Emactuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14907",
                        "description": "The risk or severity of adverse effects can be increased when Bevacizumab zirconium Zr 89 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14908",
                        "description": "The risk or severity of adverse effects can be increased when Refanezumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14919",
                        "description": "The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14947",
                        "description": "The risk or severity of adverse effects can be increased when Bermekimab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14952",
                        "description": "The risk or severity of adverse effects can be increased when Pamrevlumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14959",
                        "description": "The risk or severity of adverse effects can be increased when Opicinumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14962",
                        "description": "The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14967",
                        "description": "The risk or severity of adverse effects can be increased when Margetuximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14988",
                        "description": "The risk or severity of adverse effects can be increased when Dalantercept is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB14997",
                        "description": "The risk or severity of adverse effects can be increased when Pateclizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15014",
                        "description": "The risk or severity of adverse effects can be increased when Gremubamab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15022",
                        "description": "The risk or severity of adverse effects can be increased when Apomab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15044",
                        "description": "The risk or severity of adverse effects can be increased when Tafasitamab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15045",
                        "description": "The risk or severity of adverse effects can be increased when Ipafricept is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15076",
                        "description": "The risk or severity of adverse effects can be increased when Abrilumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15089",
                        "description": "The risk or severity of adverse effects can be increased when Frovocimab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15090",
                        "description": "The risk or severity of adverse effects can be increased when Tezepelumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15101",
                        "description": "The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15104",
                        "description": "The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15113",
                        "description": "The risk or severity of adverse effects can be increased when Utomilumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15118",
                        "description": "The risk or severity of adverse effects can be increased when Zolbetuximab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15135",
                        "description": "The risk or severity of adverse effects can be increased when Ponezumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15160",
                        "description": "The risk or severity of adverse effects can be increased when Asunercept is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15172",
                        "description": "The risk or severity of adverse effects can be increased when Suvratoxumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15225",
                        "description": "The risk or severity of adverse effects can be increased when Mitazalimab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15252",
                        "description": "The risk or severity of adverse effects can be increased when Nemolizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15253",
                        "description": "The risk or severity of adverse effects can be increased when Bleselumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15277",
                        "description": "The risk or severity of adverse effects can be increased when Gedivumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15336",
                        "description": "The risk or severity of adverse effects can be increased when Valanafusp alfa is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15349",
                        "description": "The risk or severity of adverse effects can be increased when Sofituzumab vedotin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15354",
                        "description": "The risk or severity of adverse effects can be increased when Evinacumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15363",
                        "description": "The risk or severity of adverse effects can be increased when Istiratumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15383",
                        "description": "The risk or severity of adverse effects can be increased when Pidilizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15397",
                        "description": "The risk or severity of adverse effects can be increased when GMA 161 is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15409",
                        "description": "The risk or severity of adverse effects can be increased when Ladiratuzumab vedotin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15415",
                        "description": "The risk or severity of adverse effects can be increased when Tomaralimab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15428",
                        "description": "The risk or severity of adverse effects can be increased when Vesencumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15432",
                        "description": "The risk or severity of adverse effects can be increased when Pinatuzumab vedotin is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15441",
                        "description": "The risk or severity of adverse effects can be increased when Lulizumab pegol is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15443",
                        "description": "The risk or severity of adverse effects can be increased when Lorukafusp alfa is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15453",
                        "description": "The risk or severity of adverse effects can be increased when Naratuximab emtansine is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15559",
                        "description": "The risk or severity of adverse effects can be increased when Zenocutuzumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15898",
                        "description": "The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Atoltivimab"
                    },
                    {
                        "drugbank-id": "DB15899",
                        "description": "The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Maftivimab"
                    },
                    {
                        "drugbank-id": "DB15900",
                        "description": "The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Odesivimab"
                    },
                    {
                        "drugbank-id": "DB00177",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Valsartan"
                    },
                    {
                        "drugbank-id": "DB00213",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Pantoprazole"
                    },
                    {
                        "drugbank-id": "DB00345",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Aminohippuric acid"
                    },
                    {
                        "drugbank-id": "DB00394",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Beclomethasone dipropionate"
                    },
                    {
                        "drugbank-id": "DB00520",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Caspofungin"
                    },
                    {
                        "drugbank-id": "DB00583",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Levocarnitine"
                    },
                    {
                        "drugbank-id": "DB00588",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Fluticasone propionate"
                    },
                    {
                        "drugbank-id": "DB00602",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Ivermectin"
                    },
                    {
                        "drugbank-id": "DB00646",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Nystatin"
                    },
                    {
                        "drugbank-id": "DB00701",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Amprenavir"
                    },
                    {
                        "drugbank-id": "DB00762",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Irinotecan"
                    },
                    {
                        "drugbank-id": "DB00778",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Roxithromycin"
                    },
                    {
                        "drugbank-id": "DB00795",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Sulfasalazine"
                    },
                    {
                        "drugbank-id": "DB00976",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Telithromycin"
                    },
                    {
                        "drugbank-id": "DB01051",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Novobiocin"
                    },
                    {
                        "drugbank-id": "DB01092",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Ouabain"
                    },
                    {
                        "drugbank-id": "DB01095",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Fluvastatin"
                    },
                    {
                        "drugbank-id": "DB01241",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Gemfibrozil"
                    },
                    {
                        "drugbank-id": "DB01264",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Darunavir"
                    },
                    {
                        "drugbank-id": "DB01393",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Bezafibrate"
                    },
                    {
                        "drugbank-id": "DB01645",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Genistein"
                    },
                    {
                        "drugbank-id": "DB01892",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Hyperforin"
                    },
                    {
                        "drugbank-id": "DB04216",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Quercetin"
                    },
                    {
                        "drugbank-id": "DB04850",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Posizolid"
                    },
                    {
                        "drugbank-id": "DB05928",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Dovitinib"
                    },
                    {
                        "drugbank-id": "DB06151",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Acetylcysteine"
                    },
                    {
                        "drugbank-id": "DB06210",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Eltrombopag"
                    },
                    {
                        "drugbank-id": "DB08862",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Cholecystokinin"
                    },
                    {
                        "drugbank-id": "DB08864",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Rilpivirine"
                    },
                    {
                        "drugbank-id": "DB08880",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Teriflunomide"
                    },
                    {
                        "drugbank-id": "DB08906",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Fluticasone furoate"
                    },
                    {
                        "drugbank-id": "DB09198",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Lobeglitazone"
                    },
                    {
                        "drugbank-id": "DB09272",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Eluxadoline"
                    },
                    {
                        "drugbank-id": "DB09292",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Sacubitril"
                    },
                    {
                        "drugbank-id": "DB09298",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Silibinin"
                    },
                    {
                        "drugbank-id": "DB11936",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Bempedoic acid"
                    },
                    {
                        "drugbank-id": "DB12978",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Pexidartinib"
                    },
                    {
                        "drugbank-id": "DB13867",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Fluticasone"
                    },
                    {
                        "drugbank-id": "DB13919",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Candesartan"
                    },
                    {
                        "drugbank-id": "DB13955",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Estradiol dienanthate"
                    },
                    {
                        "drugbank-id": "DB15444",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Elexacaftor"
                    },
                    {
                        "drugbank-id": "DB04348",
                        "description": "Taurocholic acid may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy"
                    },
                    {
                        "drugbank-id": "DB01174",
                        "description": "Phenobarbital may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy"
                    },
                    {
                        "drugbank-id": "DB01234",
                        "description": "Dexamethasone may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy"
                    },
                    {
                        "drugbank-id": "DB03619",
                        "description": "Deoxycholic acid may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy"
                    },
                    {
                        "drugbank-id": "DB00255",
                        "description": "Diethylstilbestrol may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00220",
                        "description": "Nelfinavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00224",
                        "description": "Indinavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00227",
                        "description": "Lovastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00328",
                        "description": "Indomethacin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00412",
                        "description": "Rosiglitazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00439",
                        "description": "Cerivastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00586",
                        "description": "Diclofenac may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00622",
                        "description": "Nicardipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00975",
                        "description": "Dipyridamole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01072",
                        "description": "Atazanavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01076",
                        "description": "Atorvastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01098",
                        "description": "Rosuvastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB08860",
                        "description": "Pitavastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB12319",
                        "description": "Benzbromarone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00175",
                        "description": "Pravastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00176",
                        "description": "Fluvoxamine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00222",
                        "description": "Glimepiride may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00270",
                        "description": "Isradipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00301",
                        "description": "Flucloxacillin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00335",
                        "description": "Atenolol may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00342",
                        "description": "Terfenadine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00421",
                        "description": "Spironolactone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00455",
                        "description": "Loratadine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00572",
                        "description": "Atropine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00619",
                        "description": "Imatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00625",
                        "description": "Efavirenz may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00678",
                        "description": "Losartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00693",
                        "description": "Fluorescein may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00698",
                        "description": "Nitrofurantoin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00788",
                        "description": "Naproxen may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00822",
                        "description": "Disulfiram may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00833",
                        "description": "Cefaclor may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00911",
                        "description": "Tinidazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00912",
                        "description": "Repaglinide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00966",
                        "description": "Telmisartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00973",
                        "description": "Ezetimibe may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01015",
                        "description": "Sulfamethoxazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01023",
                        "description": "Felodipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01039",
                        "description": "Fenofibrate may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01054",
                        "description": "Nitrendipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01067",
                        "description": "Glipizide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01138",
                        "description": "Sulfinpyrazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01149",
                        "description": "Nefazodone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01165",
                        "description": "Ofloxacin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01222",
                        "description": "Budesonide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB02123",
                        "description": "Glycochenodeoxycholic Acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB05804",
                        "description": "Prasterone sulfate may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB09374",
                        "description": "Indocyanine green acid form may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB12712",
                        "description": "Pilsicainide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB13345",
                        "description": "Dihydroergocristine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB13751",
                        "description": "Glycyrrhizic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00570",
                        "description": "Vinblastine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB01229",
                        "description": "Paclitaxel may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00390",
                        "description": "Digoxin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00541",
                        "description": "Vincristine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00637",
                        "description": "Astemizole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00694",
                        "description": "Daunorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00997",
                        "description": "Doxorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB00451",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Levothyroxine"
                    },
                    {
                        "drugbank-id": "DB05016",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Ataluren"
                    },
                    {
                        "drugbank-id": "DB06749",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Ginsenoside Rb1"
                    },
                    {
                        "drugbank-id": "DB11942",
                        "description": "The excretion of Belantamab mafodotin can be decreased when combined with Selinexor"
                    },
                    {
                        "drugbank-id": "DB05773",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Trastuzumab emtansine"
                    },
                    {
                        "drugbank-id": "DB05889",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Inotuzumab ozogamicin"
                    },
                    {
                        "drugbank-id": "DB08870",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Brentuximab vedotin"
                    },
                    {
                        "drugbank-id": "DB00877",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Sirolimus"
                    },
                    {
                        "drugbank-id": "DB01590",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Everolimus"
                    },
                    {
                        "drugbank-id": "DB06589",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Pazopanib"
                    },
                    {
                        "drugbank-id": "DB06626",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Axitinib"
                    },
                    {
                        "drugbank-id": "DB06772",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Cabazitaxel"
                    },
                    {
                        "drugbank-id": "DB08912",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Dabrafenib"
                    },
                    {
                        "drugbank-id": "DB05239",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Cobimetinib"
                    },
                    {
                        "drugbank-id": "DB00188",
                        "description": "The serum concentration of Bortezomib can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00248",
                        "description": "The serum concentration of Cabergoline can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00441",
                        "description": "The serum concentration of Gemcitabine can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00458",
                        "description": "The serum concentration of Imipramine can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00540",
                        "description": "The serum concentration of Nortriptyline can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00726",
                        "description": "The serum concentration of Trimipramine can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00773",
                        "description": "The serum concentration of Etoposide can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00970",
                        "description": "The serum concentration of Dactinomycin can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB01030",
                        "description": "The serum concentration of Topotecan can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB01254",
                        "description": "The serum concentration of Dasatinib can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB01396",
                        "description": "The serum concentration of Digitoxin can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06176",
                        "description": "The serum concentration of Romidepsin can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06212",
                        "description": "The serum concentration of Tolvaptan can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06603",
                        "description": "The serum concentration of Panobinostat can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06616",
                        "description": "The serum concentration of Bosutinib can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB06769",
                        "description": "The serum concentration of Bendamustine can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB08910",
                        "description": "The serum concentration of Pomalidomide can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09063",
                        "description": "The serum concentration of Ceritinib can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09330",
                        "description": "The serum concentration of Osimertinib can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11641",
                        "description": "The serum concentration of Vinflunine can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11760",
                        "description": "The serum concentration of Talazoparib can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11967",
                        "description": "The serum concentration of Binimetinib can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12001",
                        "description": "The serum concentration of Abemaciclib can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12483",
                        "description": "The serum concentration of Copanlisib can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB09054",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Idelalisib"
                    },
                    {
                        "drugbank-id": "DB09297",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Paritaprevir"
                    },
                    {
                        "drugbank-id": "DB11796",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Fostemsavir"
                    },
                    {
                        "drugbank-id": "DB14761",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Remdesivir"
                    },
                    {
                        "drugbank-id": "DB11817",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Baricitinib"
                    },
                    {
                        "drugbank-id": "DB00295",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Morphine"
                    },
                    {
                        "drugbank-id": "DB00300",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Tenofovir disoproxil"
                    },
                    {
                        "drugbank-id": "DB00349",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Clobazam"
                    },
                    {
                        "drugbank-id": "DB00612",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Bisoprolol"
                    },
                    {
                        "drugbank-id": "DB00742",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Mannitol"
                    },
                    {
                        "drugbank-id": "DB00836",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Loperamide"
                    },
                    {
                        "drugbank-id": "DB00882",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Clomifene"
                    },
                    {
                        "drugbank-id": "DB00950",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Fexofenadine"
                    },
                    {
                        "drugbank-id": "DB01079",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Tegaserod"
                    },
                    {
                        "drugbank-id": "DB01261",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Sitagliptin"
                    },
                    {
                        "drugbank-id": "DB01263",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Posaconazole"
                    },
                    {
                        "drugbank-id": "DB01394",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Colchicine"
                    },
                    {
                        "drugbank-id": "DB05015",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Belinostat"
                    },
                    {
                        "drugbank-id": "DB05039",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Indacaterol"
                    },
                    {
                        "drugbank-id": "DB06207",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Silodosin"
                    },
                    {
                        "drugbank-id": "DB06228",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Rivaroxaban"
                    },
                    {
                        "drugbank-id": "DB06403",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ambrisentan"
                    },
                    {
                        "drugbank-id": "DB06605",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Apixaban"
                    },
                    {
                        "drugbank-id": "DB06670",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Odanacatib"
                    },
                    {
                        "drugbank-id": "DB06695",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Dabigatran etexilate"
                    },
                    {
                        "drugbank-id": "DB08930",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Dolutegravir"
                    },
                    {
                        "drugbank-id": "DB08934",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Sofosbuvir"
                    },
                    {
                        "drugbank-id": "DB09039",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Eliglustat"
                    },
                    {
                        "drugbank-id": "DB09075",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Edoxaban"
                    },
                    {
                        "drugbank-id": "DB09076",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Umeclidinium"
                    },
                    {
                        "drugbank-id": "DB09079",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Nintedanib"
                    },
                    {
                        "drugbank-id": "DB09161",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Technetium Tc 99m sestamibi"
                    },
                    {
                        "drugbank-id": "DB09183",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Dasabuvir"
                    },
                    {
                        "drugbank-id": "DB09296",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ombitasvir"
                    },
                    {
                        "drugbank-id": "DB11362",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Selexipag"
                    },
                    {
                        "drugbank-id": "DB11574",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Elbasvir"
                    },
                    {
                        "drugbank-id": "DB11575",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Grazoprevir"
                    },
                    {
                        "drugbank-id": "DB11689",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Selumetinib"
                    },
                    {
                        "drugbank-id": "DB11712",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Tezacaftor"
                    },
                    {
                        "drugbank-id": "DB11770",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Talinolol"
                    },
                    {
                        "drugbank-id": "DB11827",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ertugliflozin"
                    },
                    {
                        "drugbank-id": "DB11855",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Revefenacin"
                    },
                    {
                        "drugbank-id": "DB11951",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Lemborexant"
                    },
                    {
                        "drugbank-id": "DB11952",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Duvelisib"
                    },
                    {
                        "drugbank-id": "DB11995",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Avatrombopag"
                    },
                    {
                        "drugbank-id": "DB12141",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Gilteritinib"
                    },
                    {
                        "drugbank-id": "DB12364",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Betrixaban"
                    },
                    {
                        "drugbank-id": "DB12455",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Omadacycline"
                    },
                    {
                        "drugbank-id": "DB12457",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Rimegepant"
                    },
                    {
                        "drugbank-id": "DB12825",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Lefamulin"
                    },
                    {
                        "drugbank-id": "DB12836",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Grapiprant"
                    },
                    {
                        "drugbank-id": "DB12887",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Tazemetostat"
                    },
                    {
                        "drugbank-id": "DB12941",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Darolutamide"
                    },
                    {
                        "drugbank-id": "DB13007",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Enfortumab vedotin"
                    },
                    {
                        "drugbank-id": "DB13125",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Lusutrombopag"
                    },
                    {
                        "drugbank-id": "DB14126",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Tenofovir"
                    },
                    {
                        "drugbank-id": "DB14631",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Prednisolone phosphate"
                    },
                    {
                        "drugbank-id": "DB14723",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Larotrectinib"
                    },
                    {
                        "drugbank-id": "DB15328",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Ubrogepant"
                    },
                    {
                        "drugbank-id": "DB15982",
                        "description": "The serum concentration of Berotralstat can be increased when it is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB12147",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Erdafitinib"
                    },
                    {
                        "drugbank-id": "DB11732",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Lasmiditan"
                    },
                    {
                        "drugbank-id": "DB15595",
                        "description": "The therapeutic efficacy of Ebola Zaire vaccine live attenuated can be decreased when used in combination with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11652",
                        "description": "Tucatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level"
                    },
                    {
                        "drugbank-id": "DB14845",
                        "description": "The serum concentration of Belantamab mafodotin can be increased when it is combined with Filgotinib"
                    },
                    {
                        "drugbank-id": "DB15258",
                        "description": "The therapeutic efficacy of Belantamab mafodotin can be decreased when used in combination with Imlifidase"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}